Inventiva S.A. (IVA)
| Market Cap | 932.40M +21.4% |
| Revenue (ttm) | 7.94M -52.0% |
| Net Income | -415.80M |
| EPS | -2.23 |
| Shares Out | 207.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,713,179 |
| Open | 4.250 |
| Previous Close | 4.140 |
| Day's Range | 3.910 - 4.260 |
| 52-Week Range | 3.350 - 7.983 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | 14.62 (+263.68%) |
| Earnings Date | Sep 25, 2026 |
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr... [Read more]
Financial Performance
In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for IVA stock is "Strong Buy." The 12-month stock price target is $14.62, which is an increase of 263.68% from the latest price.
News
RUBIS: H1 2026 Results - Strong performance leading way to upgrade of 2026 guidance
Paris, 08 September 2026, 7:00am EBITDA at €434m, +18% yoy reflecting sustained demand, disciplined execution and optimised inventory management in a volatile and high oil price context, highlighting ...
Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4
(RTTNews) - Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, on Thursday announced the last patient visit in the Phase 3 NATiV3 trial for Lanifibranor in treating metabolic dysfunctio...
Inventiva announces last patient visit in NATiV3 trial
Inventiva (IVA) announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate…
Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout
(RTTNews) - Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, on Monday announced the appointment of Chris Benecchi as Chief Operating Officer (COO).
Inventiva appoints Chris Benecchi as COO
Inventiva (IVA) announced the appointment of Chris Benecchi as COO. Benecchi will lead Inventiva’s operational readiness as the company approaches its NATiV3 Phase 3 topline study results of lanifibra...
Inventiva Appoints Chris Benecchi as Chief Operating Officer
Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026...
Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Earnings release: Q2 2026
Inventiva released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Inventiva Earnings release: Q2 2026
Inventiva released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Inventiva initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Inventiva (IVA) with an Overweight rating and no price target The investment thesis is centered on lanifibranor, which is currently in a...
Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026
Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Claret Capital Partners participates in €130m financing for Inventiva
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on t...
Inventiva Transcript: Jefferies Global Healthcare Conference 2026
A recapitalized, single-asset company is advancing lanifibranor for F2/F3 MASH, with phase III top-line data expected in Q4 2024 and a commercial launch targeted for 2028. The product is positioned to compete strongly in diabetic and fibrosis-driven segments.
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva files automatic mixed securities shelf
06:12 EDT Inventiva (IVA) files automatic mixed securities shelf
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Reports 2026 First Quarter Financial Information¹
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva Earnings release: Q1 2026
Inventiva released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.
Inventiva Earnings release: Q1 2026
Inventiva released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.